Eli Lilly (LLY) stock in focus as EU drug regular declines to endorse heart failure as a new indication for the company's GLP ...

Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...

(RTTNews) - Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Wegovy (semaglutide 2 ...

Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function Wegovy® (semaglutide 2.4 mg) is the first obesity ...

After Abiomed’s attempts to expand the user pool for its Impella RP heart pump were less than successful, the FDA has updated the wording of the device’s label to direct it toward only the patients ...

Let's be real. You're standing in the grocery aisle, reaching for that box of granola with the big red heart symbol splashed ...

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly ...

Just over a year since AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular (CV) death and heart failure–related hospitalizations for ...

Credit: FDA. These products were distributed nationwide. Marlex Pharmaceuticals is recalling 1 lot of Digoxin Tablets 0.125mg and 1 lot of Digoxin Tablets 0.25mg due to a label mix-up. According to ...